Published: Fri, October 27, 2017
Health | By Jay Jacobs

AbbVie Inc. (NASDAQ:ABBV) Expected To Report Earnings On Friday


In terms of the outlook for the 2017 full year, AbbVie sees EPS in the range of $5.53 to $5.55. Acrospire Investment Management LLC now owns 2,604 shares of the company's stock valued at $189,000 after acquiring an additional 1,800 shares during the period. The company's price to sales ratio for trailing twelve months is - and price to book ratio for most recent quarter is 2.00, whereas price to cash per share for the most recent quarter is 2.02.

BZUN's shares were trading -25.81% below from the 52-week high price mark of $40.65 and 177.46% above from the 52-week price bottom of $10.87.

Analysts look for public financial statements, listen in on conference calls and talk to managers and customers of a company in order to reach an opinion and communicate the value of a stock. Investors measure stock performance on the basis of a company's earnings power. Evercore ISI began coverage on shares of AbbVie in a report on Wednesday, August 16th. Tctc Limited Liability reported 0.84% of its portfolio in AbbVie Inc (NYSE:ABBV).

In other AbbVie news, Director Edward J. Rapp acquired 4,000 shares of the firm's stock in a transaction that occurred on Monday, July 31st. The stock is now moving below its 20-Day Simple Moving Average of -2.37% with a 50-Day Simple Moving Average of 5.98 percent.

AbbVie's pipeline drugs upadacitinib and risankizumab have been successful in recent trials, offering hope the company could access billion dollar markets if they are approved.

Receive AbbVie Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. with MarketBeat.com's FREE daily email newsletter.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 28th. The company net profit margin is 3.30% and gross profit margin is 46.70%. For the quarter ending Mar-18, 6 analysts have a mean sales target of 7,078.54 million whilst for the year ending Dec-17, 17 analysts have a mean target of 27,965.90 million. First Heartland Consultants has 0.23% invested in AbbVie Inc (NYSE:ABBV) for 12,416 shares.

Humira, which is approved to treat psoriasis and rheumatoid arthritis, raked in $16.08 billion in sales previous year, making up more than 60 percent of AbbVie's 2016 revenue.

Oct 27 (Reuters) - AbbVie Inc forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago, driving the USA drugmaker's shares up 4 percent on Friday. Stockholders of record on Friday, October 13th will be given a $0.64 dividend. The ex-dividend date of this dividend is Wednesday, October 12th. The stock now has Weekly Volatility of 3.63% and Monthly Volatility of 2.41%. AbbVie's dividend payout ratio is now 62.90%. The firm has "Overweight" rating by Morgan Stanley given on Monday, November 2. The rating was maintained by SunTrust with "Buy" on Monday, October 16. The stock of AbbVie Inc (NYSE:ABBV) has "Buy" rating given on Friday, July 14 by Jefferies. As per Monday, September 11, the company rating was maintained by Roth Capital. 0 analysts gave its stock an Outperform rating.

In a note issued to investors and clients on 27 October, Shore Capital maintained their Sell rating on Hastings Group Holdings Plc (LON:HSTG)'s stock. Schumacher Laura J had sold 79,800 shares worth $5.59M. Following the completion of the transaction, the insider now owns 144,138 shares in the company, valued at approximately $9,368,970. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. First Comml Bank Of Omaha reported 0.08% of its portfolio in AbbVie Inc (NYSE:ABBV). The company has market cap of 2.12 billion GBP. However, though Humira is doing well, the company is concerned about the product's long-term growth prospects, given the potential biosimilar competition. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.

Like this: